Alnylam price target raised to $125 from $82 at Leerink Leerink raised its price target for Alnylam shares to $125 citing the company's "impressive" partnership with Genzyme. The firm keeps an Outperform rating on the stock.
News For ALNY From The Last 14 Days
Check below for free stories on ALNY the last two weeks.
Alnylam COO critical of big pharma, FierceDrugDelivery reports After Novartis (NVS) decided to end its RNAi research, Alnylam COO Barry Greene told FierceDrugDelivery that big pharma has "never been able to innovate." Greene attributes the recent sell-off in Alnylam shares to "generally bearish sentiment on Wall Street regarding biotech stocks in particular." Reference Link